EPHA2激酶域新突变p.G668D导致先天性白内障并影响受体稳定性与功能
研究在一个四代常染色体显性先天性后囊下白内障中国家系中,通过靶向NGS和Sanger测序鉴定出EPHA2激酶域新杂合错义突变c.2003G>A(p.G668D)。功能实验显示该突变经蛋白酶体途径降低EphA2蛋白水平(P=0.036),改变其亚细胞定位及β-catenin分布,并显著促进人晶状体上皮细胞迁移(P=0.002)。
要点
- EPHA2激酶域p.G668D是第三个在该域报道的先天性白内障突变。
- 突变经蛋白酶体途径降低EphA2蛋白水平(P=0.036)。
- 突变改变EphA2亚细胞定位并显著促进晶状体上皮细胞迁移(P=0.002)。
核心结论
- EPHA2激酶域p.G668D突变导致常染色体显性先天性后囊下白内障。
- 该突变使受体不稳定、改变亚细胞定位并改变EphA2与其配体ephrin的激活。
- 突变型EphA2减弱对细胞迁移的抑制,促进细胞迁移并导致白内障形成。
研究设计与样本
- 研究一个四代常染色体显性先天性后囊下白内障中国家系。
- 用靶向NGS筛查54个白内障相关基因,并经Sanger测序验证。
- 体外合成EPHA2野生型cDNA,用PCR定点诱变构建p.G668D突变体。
- 用Western blotting和荧光显微镜分析蛋白表达水平与亚细胞定位。
- 用伤口愈合实验分析细胞迁移变化。
主要发现
- 鉴定出EPHA2激酶域新颖杂合错义突变c.2003G>A(p.G668D)。
- 该突变为该激酶域报道的第三个先天性白内障突变。
- p.G668D经蛋白酶体依赖途径降低EphA2蛋白水平(P=0.036)。
- 突变使EphA2从细胞-细胞接触处变为弥漫性膜周分布,并改变β-catenin分布。
- 突变型EphA2显著促进人晶状体上皮细胞迁移(P=0.002)。
关键数值与推荐
- 家系为四代常染色体显性先天性后囊下白内障。
- 靶向NGS筛查54个白内障相关基因。
- 突变c.2003G>A导致p.G668D,位于EPHA2激酶域。
- p.G668D降低EphA2蛋白水平(P=0.036)。
- 突变型EphA2促进人晶状体上皮细胞迁移(P=0.002)。
临床怎么用
- 对常染色体显性先天性后囊下白内障家系可考虑EPHA2激酶域基因筛查。
- EPHA2激酶域突变的功能后果涉及受体稳定性与细胞迁移调控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify the genetic defect in a four-generation Chinese family that causes autosomal dominant congenital posterior subcapsular cataracts, and to understand how this EPHA2 kinase domain mutation affects EPHA2 activity. METHODS: Variants in 54 cataract-associated genes were screened by targeted next generation sequencing (NGS) and then validated by Sanger sequencing. EPHA2 wild-type cDNA was synthesized in vitro, and EPHA2 p.G668D mutant was constructed by PCR site-directed mutagenesis. Western blotting and fluorescence microscopy were used to analyze the expression level of protein and its subcellular localization, respectively. A wound-healing assay was performed to analyze changes to cell migration. RESULTS: A novel heterozygous missense mutation was identified in the kinase domain of the EPHA2 gene (c.2003G>A, p.G668D). This is the third congenital cataract mutation being reported in this domain. Functional study revealed that the kinase domain mutation (p.G668D) decreased EphA2 protein level (P = 0.036) via a proteasome-dependent pathway, altered its subcellular localization of the EphA2 from cell-cell contacts to a diffuse perimembranous distribution, and changed the distribution of β-catenin as well. The expression of mutant EphA2 significantly promoted the migration of human lens epithelial cells (P = 0.002). CONCLUSIONS: Our study presented the evidence for a novel EPHA2 kinase domain mutation that causes congenital posterior subcapsular cataracts. The first functional study on an EPHA2 kinase domain mutation that causes a congenital cataract revealed that the G668D mutation destabilized the receptor, changed its subcellular localization, and altered the activation of EphA2 with its ligand ephrin. The mutant EphA2 resulted in a reduced inhibition of cell migration. As a consequence, the c.G668D mutation promoted cell migration and caused the formation of cataracts.
引用
- Zhai Y, Zhu S, Li J, et al. A Novel Human Congenital Cataract Mutation in EPHA2 Kinase Domain (p.G668D) Alters Receptor Stability and Function. Invest Ophthalmol Vis Sci. 2019. PMID: 31725171. doi:10.1167/iovs.19-27370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。